
Monte Rosa Therapeutics fell 31.2% from $13.61 to $9.37, behind the S&P 500's +13.3%. Its worst day was Jul 31 (−27.2%), and its low came Nov 12 at $9.31.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Monte Rosa Therapeutics shares rose 13.4%, while the S&P 500 fell 0.3%.
+13.4% · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
Monte Rosa Therapeutics closed at its highest level of the year, 86.0% above where the year started.
+8.7% · S&P 500 0.0%
EPS of $-0.55 missed the $-0.39 estimate on $2.8M revenue (est. $13.4M).
−2.0% · S&P 500 +0.3%
EPS of $-0.45 missed the $-0.36 estimate on $4.2M revenue (est. $13.4M).
−2.8% · S&P 500 −0.3%
EPS of $-0.43 missed the $-0.34 estimate on $9.0M revenue (est. $15.4M).
+0.6% · S&P 500 −0.2%
EPS of $0.03 beat the $-0.18 estimate on $54.4M revenue (est. $36.2M).
−5.3% · S&P 500 −4.4%
Where it ended: a close of $9.37 on Nov 13, 2026. Up next: Q4 2026 earnings on Mar 16, 2027 (EPS est. $-0.18, revenue est. $35.2M).
Nothing in the past 12 months.
All GLUE dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GLUE and SPY from Benzinga historical bars. Not investment advice.